Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma
NCT05340491Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Apr 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05340491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340491.